Free Access
Editorial
Issue
Med Sci (Paris)
Volume 27, Number 10, Octobre 2011
Page(s) 795 - 797
Section Éditorial
DOI https://doi.org/10.1051/medsci/20112710001
Published online 21 October 2011
  1. Tartour E, Fridman WH, Bonnefoy JY, Sandoval F. Immunothérapie des cancers : succès récents et futures directions. Med Sci (Paris) 2011 ; 27 : 833–841. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004 ; 10 : 909–915. [CrossRef] [PubMed] [Google Scholar]
  3. Chouaib S, El Hage F, Benlalam H, Mami-Chouaib F. Immunothérapie du cancer : espoirs et réalités. Med Sci (Paris) 2006 ; 22 : 755–759. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Sawyers C. Targeted cancer therapy. Nature 2004 ; 432 : 294–297. [CrossRef] [PubMed] [Google Scholar]
  5. Kaiser J. Combining targeted drugs to stop resistant tumors. Science 2011 ; 331 : 1542–1545. [CrossRef] [PubMed] [Google Scholar]
  6. Sakaguchi S, Wing K, Onishi Y, et al. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009 ; 21 : 1105–1111. [CrossRef] [PubMed] [Google Scholar]
  7. Nishikawa H, Sakaguchi S. Regulatory cells in tumor immunity. Int J Cancer 2010; 127 : 759–767. [PubMed] [Google Scholar]
  8. Poschke I, Mougiakakos D, Kiessling R.. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 2011 ; 60 : 1161–1171. [CrossRef] [PubMed] [Google Scholar]
  9. Chaput N, Darrasse-Jeze G, Bergot AS, et al. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 2007 ; 179 : 4969–4978. [PubMed] [Google Scholar]
  10. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011 ; 60 : 909–918. [CrossRef] [PubMed] [Google Scholar]
  11. Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999 ; 59 : 3128–3133. [PubMed] [Google Scholar]
  12. Golgher D, Jones E, Powrie F, et al. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002 ; 32 : 3267–3275. [CrossRef] [PubMed] [Google Scholar]
  13. Teng MW, Swann JB, von Scheidt B, et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 2010 ; 70 : 2665–2674. [CrossRef] [PubMed] [Google Scholar]
  14. Darrasse-Jeze G, Bergot AS, Durgeau A, et al. Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 2009 ; 119 : 2648–2662. [PubMed] [Google Scholar]
  15. Maury S, Lemoine FM, Hicheri Y, et al. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2011 ; 2 : 41–52. [Google Scholar]
  16. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011 ; 365 : 725–733. [CrossRef] [PubMed] [Google Scholar]
  17. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011 ; 3 : 95–73. [CrossRef] [Google Scholar]
  18. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011 ; 8 : 151–160. [CrossRef] [PubMed] [Google Scholar]
  19. Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009 ; 206 : 1717–1725. [CrossRef] [PubMed] [Google Scholar]
  20. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008 ; 322 : 271–275. [CrossRef] [PubMed] [Google Scholar]
  21. Menard C, Ghiringhelli F, Roux S, et al. CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res 2008 ; 14 : 5242–5249. [CrossRef] [PubMed] [Google Scholar]
  22. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001 ; 19 : 565–594. [CrossRef] [PubMed] [Google Scholar]
  23. Olive D, le Thi S, Xerri L, et al. Rôle de CTLA-4 dans la cosignalisation négative du systeme immunitaire. Med Sci (Paris) 2011 ; 27 : 842–849. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  24. Robert C, Mateus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome metastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.